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Abstract
Opioid prescriptions for chronic pain and subsequent opioid-related complications have
risen dramatically in the US. Recent data suggest that medical marijuana laws have been
associated with lower state-level opioid overdose mortality. In a national survey, we exam-
ined the prevalence of substitution of marijuana for opioids among US adults taking opioids
for pain.Using GfK’s KnowledgePanel, we conducted an Internet-based survey of a nation-
ally representative sample of 16,280 adults in 2017 about individual perceptions and use of
marijuana. We developed questions designed to assess the extent and reasons for substitu-
tion of marijuana for opioids. We examined opioid substitution among respondents with a
history of ever using marijuana who used opioids in the past 12 months. There were 9,003
respondents, corresponding to a 55.3% response rate. The mean age was 48 years.
Among the 5% (n = 486) who reported ever using marijuana and using opioids in the past
year, 43% used opioids daily, and 23% reported current (past 30 day) marijuana use. Forty-
one percent reported a decrease or cessation of opioid use due to marijuana use; 46%
reported no change in opioid use; and 8% reported an increase in opioid use. We found that
a substantial number of US adults reported that they substituted marijuana for opioids.
Introduction
Chronic pain affects approximately one-third of the U.S. population, and opioid prescriptions
have substantially increased over the last 20 years [1]. In parallel, there has been an increase in
opioid-related complications, with opioid overdose deaths quadrupling between 1999 and
2015 [2]. Growing concerns about the risks of opioids, including overdose-related deaths and
opioid use disorder, have prompted greater focus on the more judicious use of these agents for
managing pain and the need to identify other agents to treat pain [3].
The data on the efficacy of cannabinoids in the management of pain is evolving. In a sys-
tematic review, there was low-strength evidence that cannabis is effective for treating neuro-
pathic pain and insufficient evidence of its effectiveness for other types of pain [4]. The
American Academy of Neurology has endorsed use of cannabinoids for the pain and spasticity
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associated with multiple sclerosis but cautions that the safety profile of cannabinoids has not
been compared to other approved drugs [5]. Despite the lack of robust evidence for efficacy of
cannabinoids in pain management, marijuana has been approved by legislatures or ballot ini-
tiative for the management of pain in over 30 states [6].
Recent data suggest that medical marijuana laws have been associated with lower state-level
opioid overdose mortality, hospitalizations related to opioid complications, detection of opi-
oids among fatally injured drivers, and prescription of analgesics [7]. These ecologic studies,
while hypothesis generating, do not inform our understanding of the individual effects of mar-
ijuana use or combined marijuana and opioid use. Prospective cohort studies and clinical trials
are needed to improve our understanding of the effects of cannabis on pain management.
Nonetheless, these studies have spurred discussion about the potential for marijuana to serve
as a substitute for opioids, particularly in contexts where marijuana is increasingly available
through legalization. Small surveys of convenience samples of American and Canadian mari-
juana users have reported that substitution of marijuana for opioids is common, ranging from
approximately 30% to 97% [8, 9]. To our knowledge, there are no nationally representative
surveys examining substitution and reasons for substitution among the general US adult popu-
lation. We examined the prevalence and reasons for substitution of marijuana for opioids
among US adults taking opioids for pain, as well as the factors associated with substitution.
Methods
Survey development
Details of survey development have been previously published [10]. The survey questions were
designed based on a review of the literature and existing national surveys and interviews with
substance abuse experts and marijuana distributors and dispensary staff [10]. The survey asks
about a wide range of topics, including perception of risks and benefits associated with mari-
juana use, comparisons of marijuana to other substances (tobacco, alcohol), and pertinent
public health questions relevant to implementing marijuana legalization. The current study is
based on the questions that were designed to assess the extent and reasons for substitution of
marijuana for opioids. All questions used Likert scales for response options and were edited to
meet an 8th-grade reading level. Prior to administration, our survey was tested on a conve-
nience sample of 40 adults to ensure question reliability and validity. Volunteers were com-
prised of a panel of patients from the investigator’s (SK, BC) clinics and were offered no
incentives to volunteer (survey available in S1 File).
We ascertained opioid use (using the colloquial term “opiate”) with the following question:
“In the past 12 months, have you regularly taken opiate medications such as Vicodin, Percocet,
or OxyContin to treat pain? Do not include pain medications that can be bought without a
prescription such as aspirin, Tylenol, or Advil.” We ascertained marijuana use with the follow-
ing questions: “Have you ever used marijuana?” and “How long has it been since you last used
marijuana?”
We ascertained substitution of marijuana for opioids as follows: “Have you noticed a
change in the amount of opiate medications you need or use for pain because of your mari-
juana use?” Response options were a) “Yes, I need a lot more opiate medication,” b) “Yes, I
need slightly more opiate medication,” c) “No change,” d) “Yes, I need slightly less opiate med-
ication,” e) “Yes, I need a lot less opiate medication,” and f) “I have been able to stop using opi-
ate medications.” Among those endorsing substitution, we also asked about reasons for
substitution. Response options were a) “Better pain management with marijuana,” b) “Fewer
side effects from marijuana,” c) “Fewer withdrawal symptoms with marijuana,” d) “Marijuana
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is easier to obtain,” e) “Marijuana is cheaper,” and f) “More social acceptance from marijuana
use.” Multiple selections were allowed for these follow-up questions.
Sampling strategy
In 2017, we conducted an Internet-based survey of 16,280 adults about perceptions of marijuana
using KnowledgePanel (GfK Custom Research North America), a nationally representative
panel of the civilian, noninstitutionalized US population (aged�18 years) [10]. KnowledgePanel
has been in use for surveying public opinion since 1999 [11–14]. GfK created a representative
sample of US adults by random sampling of addresses [15]. The address-based sampling (ABS)
covers 97% of the country and encompasses a statistical representation of the US population.
Adults were invited to join through mailings, postcards, and follow up letters. Nonresponding
households were called. Participation included: completing and mailing back the paper invita-
tion; calling a toll-free number provided by GfK; and completing a recruitment form online [15].
All participants receive the survey in the same manner, households without Internet access are
provided with an Internet connection and a tablet to ensure participation. All participants in the
panel are sampled with a known probability of selection. No one can volunteer to participate.
Participants do not receive monetary incentives to participate but receive points that can be used
towards purchases. Participants are provided with no more than six surveys a month and are
expected to complete an average of four surveys a month. (Further details on the sampling strat-
egy of GfK’s KnowledgePanel is provided here: (https://www.gfk.com/fileadmin/user_upload/
dyna_content/US/documents/KnowledgePanel_Methodology.pdf). For the purposes of future
investigation into the role of marijuana legalization on use, California residents and young adults
aged 18 to 26 years old were oversampled. Sampling weights were provided by GfK.
Survey administration
The survey was launched on September 27, 2017 to a total of 16,280 US adults 18 years and
older and was completed on October 9, 2017. The survey was administered using an online
format. This study was considered exempt from review by the Committee on Human Subject
Research, University of California, San Francisco.
Statistical analysis
Our response rate, defined as the ratio of all respondents to all potential respondents, was
determined using methodology as outlined by the American Association for Public Opinion
Research [16]. Characteristics of the survey respondents were weighted using weights provided
by GfK to approximate the US population based on age, sex, race, ethnicity, education, house-
hold income, home ownership and metropolitan area. All analyses used weighting commands
using the weight variable provided by GfK to generate national estimates. To determine how
well our sample compared to a national federally-sponsored survey on substance abuse and
marijuana use, we first compared the socio-demographic characteristics of our survey respon-
dents to those of the National Survey on Drug Use and Health (NSDUH) [17]. NSDUH is an
annual federal survey implemented by the Substance Abuse and Mental Health Services
Administration (SAMHSA), which is an agency of the Department of Health and Human Ser-
vices (DHHS). NSDUH provides data on substance abuse epidemiology in the US [17]. We
then examined opioid substitution among respondents with a history of ever using marijuana
who used opioids in the past 12 months. We used logistic regression to determine associations
between socio-demographic characteristics (e.g., age, gender, race/ethnicity, education, house-
hold income, employment) and status of marijuana legalization in the state of residence and
substitution of marijuana for opioids. The cases who were categorized as “ever” marijuana
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users with opioid use within the past 12 months who refused to answer were excluded from
this logistic model. Analyses were conducted using R statistical software (version R-3.4.0).
There were very few participants with missing data (n = 4) and these cases were dropped from
the analysis. This study was considered exempt by the University of California, San Francisco
Committee on Human Research.
Results
There were 9,003 respondents, corresponding to a 55.3% response rate. Baseline characteristics
of respondents were similar to respondents from the National Survey on Drug Abuse and
Health, though our respondents had a slightly higher average income, (Table A in S1 File)
suggesting our sample was representative of the US population [10]. The mean age was 48
years, 48% were male, 64% were white, and 64% lived in a state in which marijuana was legal.
Among this national sample, forty-six percent reported ever using marijuana, and 8% reported
regular use of opioids for pain in the past year.
Among the 5% (n = 486) who reported ever using marijuana and using opioids in the past
year, 43% used opioids daily, and 23% reported current (past 30 day) marijuana use (Table 1).
Forty-one percent reported a decrease or cessation of opioid use due to marijuana use; 46%
reported no change in opioid use; and 8% reported an increase in opioid use. The most com-
monly reported reasons for substitution were better pain management (36%) and fewer side
effects (32%) and withdrawal symptoms (26%), compared to the non-medical reasons for use:
cheaper (13%) and more social acceptance from marijuana use (13%). In multivariable analy-
ses, we found no association between socio-demographics or status of marijuana legalization
in the state of residence and substitution (Table 2).
Discussion
In a nationally representative survey of US adults, substitution of marijuana for opioids, which
included a substantial degree of opioid discontinuation (~20%), was common. Better self-
reported pain management and fewer side effects and withdrawal symptoms were the most
common reasons for substitution. Our findings are consistent with prior surveys of American
and Canadian marijuana users in which substitution of marijuana for opioids was prevalent
due to better symptom management and fewer adverse and withdrawal effects [8].
Our study overcomes the potentially biased reporting in favor of substitution from prior
convenience samples of marijuana users. This may explain why the prevalence of substitu-
tion in our study was lower than that of other studies in which a prevalence of up to 97%
has been reported [8]. Additionally, we focused specifically on substitution of marijuana for
opioids and asked about this practice directly whereas other studies asked about substitu-
tion of marijuana for prescription drugs more broadly [18–20] or indirectly assessed opioid
substitution [21]. Our results were also inconsistent with a recently published Australian
cohort study which followed approximately 1,500 people with chronic non-cancer pain pre-
scribed opioids for four years [22]. About a third of participants reported that they some-
times or regularly reduced their opioid medication when using cannabis. However, the
prevalence of opioid discontinuation was not significantly different between daily or near-
daily marijuana users and non-users [22]. To date, data on self-reported improvement of
symptoms has not been substantiated by studies that have monitored opioid and marijuana
use. More research on this topic is clearly needed. Nonetheless, our findings suggest that
even if objective measures do not support that marijuana is substitutive for opioid use,
patients perceive that marijuana use has reduced their opioid use. Perhaps the commerciali-
zation of marijuana and the favorable media coverage surrounding the health effects of
Substitution of marijuana for opioids
PLOS ONE | https://doi.org/10.1371/journal.pone.0222577 October 4, 2019 4 / 8
marijuana are fostering such a perception [23, 24]. More research including clinical trials
on the efficacy of cannabis in pain management with the inclusion of patient-centered out-
comes is needed to shed light on the role of marijuana on pain management.
Our study has several limitations that deserve comment. Our study was a cross-sectional
survey of a relatively small number of respondents with a history of marijuana use and opioid
use within the past year. Our survey question provided a limited number of examples of opioid
medications (i.e., Vicodin, Percocet, or OxyContin), so it is possible that we did not identify all
opioid users. Although our survey specifically asked about the use of opioids for pain, it is pos-
sible that we captured individuals who were using opioids for other reasons such as opioid use
disorder. Likewise, it is possible that respondents may be using marijuana for reasons other
Table 1. Frequency of opioid and marijuana use, prevalence of substitution of marijuana for opioids, and reasons
for substitution among persons reporting marijuana and opioid use in a national survey of US adults conducted
in fall 2017.
Characteristic Ever Marijuana Users with Opioid Use
with the Past 12 Months (n = 486)
n (%)�
Frequency of Opioid Use
Daily 197 (43)
Weekly 95 (18)
Monthly 42 (9)
Less than monthly 150 (29)
Refused 2 (0)
Frequency of Marijuana Use
Current (within the past 30 days) 113 (23)
Past year (more than 30 days but within the past 12
months)
80 (15)
More than past year 293 (62)
Change in Opioid Requirement due to Marijuana Use
A lot more opioid needed 14 (4)
Slightly more opioid needed 18 (4)
No change in opioid use 244 (46)
Slightly less opioid needed 31 (8)
A lot less opioid needed 63 (13)
Stopped opioid use 93 (20)
Refused 23 (5)
Reasons for Decrease or Cessation of Opioid Use
Better pain management with marijuana 71 (36)
Fewer side effects from marijuana 63 (32)
Fewer withdrawal symptoms with marijuana 40 (26)
Marijuana is easier to obtain 22 (16)
Marijuana is cheaper 17 (13)
More social acceptance from
marijuana use
20 (13)
Other 72 (36)
Refused 4 (4)
�Numbers are unweighted, and percentages are weighted to approximate the US population. We used weights
provided by GfK to approximate the US population based on socio-demographic factors (e.g., age, gender, race,
ethnicity, education, household income, home ownership, and metropolitan area).
https://doi.org/10.1371/journal.pone.0222577.t001
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than pain. Thus, we cannot conclude with certainty that patients are using marijuana as an
alternative to opioids for pain per se. We also relied on respondents’ retrospective judgment
regarding reduction or cessation of opioid use attributable to marijuana use. Thus, our find-
ings could also be limited by recall bias, although this was minimized by restricting the sample
to those who used opioids within the past year. Underreporting of substitution could have
occurred, particularly in states in which marijuana has not been legalized.
Conclusions
In conclusion, our study provides further evidence that patients self-report that they are substi-
tuting marijuana for opioids. The impact of marijuana substitution for opioids and concomi-
tant opioid and marijuana use on health outcomes is unknown and warrants investigation.
Table 2. Characteristics associated with substitution of marijuana for opioids.
Characteristic Ever Marijuana Users with Opioid
Use with the Past 12 Months
(n = 486)
n (%)�
Did Substitute Marijuana
(n = 187)
n (%)�
Did Not Substitute Marijuana
(n = 276)
n (%)�
OR
(95% CI)
Age (years)
18–34 66 (14) 32 (51) 31 (49) 1.86 (0.91, 3.79)
35–49 115 (24) 42 (39) 66 (61) 1.03 (0.56, 1.92)
50–64 198 (41) 75 (39) 115 (61) 1.08 (0.63, 1.83)
�65 107 (22) 38 (37) 64 (63) 1.00 (ref)
Gender
Female 227 (47) 82 (39) 130 (61) 0.81 (0.55, 1.20)
Male 259 (53) 105 (42) 146 (58) 1.00 (ref)
Race/Ethnicity
Black/Non-Hispanic 47 (10) 18 (40) 27 (60) 1.03 (0.52, 2.02)
Hispanic 50 (10) 23 (48) 25 (52) 1.33 (0.70, 2.53)
Other/Non-Hispanic 31 (6) 13 (45) 16 (55) 1.30 (0.59, 2.84)
White/Non-Hispanic 358 (74) 133 (39) 208 (61) 1.00 (ref)
Education
High school or less 172 (35) 71 (45) 87 (55) 1.38 (0.79, 2.40)
Some college 179 (37) 68 (39) 106 (61) 1.12 (0.69, 1.84)
Bachelor’s degree or higher 135 (28) 48 (37) 83 (63) 1.00 (ref)
Household Income
<$20,000 114 (23) 47 (44) 61 (56) 1.01 (0.57, 1.78)
$20,000–49,999 118 (24) 49 (45) 60 (55) 1.14 (0.67, 1.94)
$50,000–74,999 75 (15) 24 (34) 47(66) 0.76 (0.42, 1.38)
�$75,000 179 (37) 67 (38) 108 (62) 1.00 (ref)
Employment Status
Not Working 256 (53) 103 (43) 139 (57) 1.25 (0.82, 1.92)
Working 230 (47) 84 (38) 137 (62) 1.00 (ref)
Status of Marijuana Legalization in State of Residence
Recreational 197 (41) 75 (40) 112 (60) 1.08 (0.67, 1.75)
Medical 129 (27) 50 (40) 74 (60) 0.94 (0.57, 1.53)
Other 160 (33) 62 (41) 90 (59) 1.00 (ref)
�Numbers are unweighted, and percentages are weighted to approximate the US population. We used weights provided by GfK to approximate the US population based
on socio-demographic factors (e.g., age, gender, race, ethnicity, education, household income, home ownership, and metropolitan area).
https://doi.org/10.1371/journal.pone.0222577.t002
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